Ranbaxy Laboratories Ltd on Tuesday launched its approved generic formulation of Clarithromycin immediate release tablets in the US market.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
The company has already received approval from the US Food & Drug Administration for marketing clarithromycin tablets.
Wockhardt Ltd said on Thursday it has received approval from USFDA for marketing antibiotic, Clarithromycin tablets, in the US market.
Ranbaxy Laboratories has received approval from the U.S. Food and Drug Administration to manufacture and market Clarithromycin XL 1,000 mg tablets.
Pharmaceutical company Ranbaxy Laboratories said on Monday its UK subsidiary has won a patent case over solvent-free clarithromycin and that it has launched the drug.
Markets ended their lowest close in 2015 on fears of FII outflows as the US Fed may hike rates.